Pharma News: Thailand Medical News Calls For Urgent Research Of Incorporating Silver Nanoparticles To Existing Antivirals To Treat COVID-19 And H5N1!
: The ongoing COVID-19 pandemic with the emergence of new variants and sub-lineages have made identifying effective treatments become even more challenging.
Unknown to many, drug resistance has developed in many of these new sub-lineages not only with the used of officially approved antivirals such as remdesivir, paxlovid, molnupiravir, favipiravir but even with drugs unofficially and illegally being repurposed to treat COVID-19 including ivermectin!
In the same light, the impending H5N1 Avian Flu pandemic has already started causing some alerts as certain preliminary unpublished data from countries like Cambodia, Chile, Bolivia and the United Kingdom are indicating that existing antivirals like Oseltamivir, Peramivir, Zanamivir and Baloxavir might not be effective against the current H5N1 bird flu infections.
There is already increasing evidence that various flu viruses and avian flu viruses can very rapidly develop resistance to antivirals that are neuraminidase inhibitors.
Thailand Medical News
is putting forward the idea of incorporating silver nanoparticles into existing antivirals, which could potentially create a more effective treatment for COVID-19 and also H5N1 along with other respiratory viruses.
Silver nanoparticles are known for their antiviral properties and have been shown to effectively inhibit viruses, including coronaviruses.
Silver nanoparticles can be synthesized using physical, chemical, or biological methods, and their high surface area makes them excellent candidates for antimicrobial applications.
Combining silver nanoparticles with existing antivirals or repurposed drugs could potentially enhance the antiviral effects of those drugs.
When silver nanoparticles come into contact with viruses, they can attach to the virus and disrupt its structure, making it less infectious. This mechanism works by disrupting the virus's outer envelope, which is essential for the virus's replication process.
What is interesting is that irrespective of any mutations arising that causes drug resistance, the silver nanoparticles are still able to inhibit these viruses.
By reducing the virus's ability to replicate, the virus is less infectious and is more easily eliminated by the body's immune system.
One proposed benefit of using silver nanoparticles in combination with existing antivirals is that the two approaches might have complementary mechanisms of action
Antiviral drugs typically target specific points in the virus's replication process, while silver nanoparticles might work by directly damaging the virus's outer envelope. Since the two approaches work differently, combining them could potentially lead to a synergistic effect and ultimately result in more effective viral inhibition.
Another potential benefit of using silver nanoparticles is that they have been shown to have low toxicity and are generally considered safe for use in humans.
This is particularly important for treatments related to COVID-19 and H5N1 infections, which requires a high level of safety and efficacy for widespread use in the general population.
Silver nanoparticles have also been used to help treat drug resistance bacterial infections.
Thailand Medical News is also developing our own line of herb and phytochemical product ranges that also incorporate silver nanoparticles.
This is nothing new as past studies and also Pharma News
coverages have detailed the exploration of such applications for a while now.
Overall, the addition of silver nanoparticles to existing antivirals represents an exciting new direction for the development of COVID-19 treatments. While further research is needed to fully understand the potential benefits of this approach, it has the potential to significantly enhance the existing antiviral treatments and offer a more effective solution to the ongoing COVID-19 pandemic and the imminent H5N1 Avian Flu pandemic.
Thailand Medical News hopes that more researchers and pharma companies would respond quickly and start delving into the development and research of a new line of drugs combining silver nanoparticles with existing antivirals and repurposed drugs to treat COVID-19 and H5N1 infections.
In conclusion, the incorporation of silver nanoparticles into existing antivirals and repurposed drugs and even herbs and phytochemicals could potentially lead to a more effective treatment for COVID-19 and also H5N1. Such combinations have the potential to offer complementary mechanisms of action and increase the overall antiviral effect, while also dealing with drug resistance issues arising in COVID-19, H5N1 and other respiratory pathogens.
For the latest Pharma News
, keep on logging to Thailand Medical News.